

SCOLR Pharma, Inc.  
Form 8-K  
August 13, 2004

**Table of Contents**

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

---

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): August 13, 2004

**SCOLR Pharma, Inc.**

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation)	000-24693 (Commission File Number)	91-1689591 (IRS Employer Identification No.)
---	---------------------------------------	--

3625 132nd Avenue SE  
Suite 300  
Bellevue, Washington 98006  
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (425) 373-0171

---

---

---

**TABLE OF CONTENTS**

Item 12. Results of Operations and Financial Condition.

SIGNATURES

EXHIBIT INDEX

EXHIBIT 99.1

---

**Table of Contents**

***Item 12. Results of Operations and Financial Condition.***

On August 13, 2004, SCOLR Pharma, Inc. issued a press release announcing its financial results for the fiscal quarter ended June 30, 2004. A copy of the press release is attached as Exhibit 99.1.

The information in this Current Report is being furnished and shall not be deemed filed for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Current Report shall not be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**SCOLR, INC.**

Dated: August 13, 2004

By: /s/ DANIEL O. WILDS  
Daniel O. Wilds  
President and Chief Executive Officer

**Table of Contents**

EXHIBIT INDEX

<b><u>Exhibit No.</u></b>	<b><u>Description</u></b>
99.1	Press Release of SCOLR Pharma dated August 13, 2004.